{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:54:34Z","timestamp":1785880474139,"version":"3.56.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005224","name":"National Center for Immunization and Respiratory Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005224","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Data on the development of neutralizing antibodies (nAbs) against SARS-CoV-2 after SARS-CoV-2 infection and after vaccination with mRNA COVID-19 vaccines are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From a prospective cohort of 3975 adult essential and frontline workers tested weekly from August 2020 to March 2021 for SARS-CoV-2 infection by reverse transcription\u2013polymerase chain reaction assay irrespective of symptoms, 497 participants had sera drawn after infection (170), vaccination (327), and after both infection and vaccination (50 from the infection population). Serum was collected after infection and each vaccine dose. Serum-neutralizing antibody titers against USA-WA1\/2020-spike pseudotype virus were determined by the 50% inhibitory dilution. Geometric mean titers (GMTs) and corresponding fold increases were calculated using t tests and linear mixed-effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 170 unvaccinated participants with SARS-CoV-2 infection, 158 (93%) developed nAbs with a GMT of 1003 (95% confidence interval, 766\u20131315). Among 139 previously uninfected participants, 138 (99%) developed nAbs after mRNA vaccine dose 2 with a GMT of 3257 (2596\u20134052). GMT was higher among those receiving mRNA-1273 vaccine (GMT, 4698; 3186\u20136926) compared with BNT162b2 vaccine (GMT, 2309; 1825\u20132919). Among 32 participants with prior SARS-CoV-2 infection, GMT was 21\u2005655 (14\u00a0766\u201331\u2005756) after mRNA vaccine dose 1, without further increase after dose 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A single dose of mRNA vaccine after SARS-CoV-2 infection resulted in the highest observed nAb response. Two doses of mRNA vaccine in previously uninfected participants resulted in higher nAbs to SARS-CoV-2 than after 1 dose of vaccine or SARS-CoV-2 infection alone. nAb response also differed by mRNA vaccine product.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciab1038","type":"journal-article","created":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T07:08:55Z","timestamp":1639811335000},"page":"e827-e837","source":"Crossref","is-referenced-by-count":9,"title":["Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection"],"prefix":"10.1093","volume":"75","author":[{"given":"Harmony L","family":"Tyner","sequence":"first","affiliation":[{"name":"St. Luke\u2019s Regional Health Care System , Duluth, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jefferey L","family":"Burgess","sequence":"additional","affiliation":[{"name":"The Mel and Enid Zuckerman College of Public Health and the College of Medicine, University of Arizona , Tucson, Arizona , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Grant","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention COVID-19 Response Team , Atlanta, Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjusha","family":"Gaglani","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Health , Temple, Texas , USA"},{"name":"Texas A&M University College of Medicine , Temple, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L","family":"Kuntz","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northwest Center for Health Research , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L","family":"Naleway","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northwest Center for Health Research , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie J","family":"Thornburg","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention COVID-19 Response Team , Atlanta, Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto J","family":"Caban-Martinez","sequence":"additional","affiliation":[{"name":"the Leonard M. Miller School of Medicine, University of Miami , Miami, Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarang K","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Family and Preventive Medicine, University of Utah Health , Salt Lake City, Utah , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan K","family":"Herring","sequence":"additional","affiliation":[{"name":"Abt Associates, Inc , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn C","family":"Beitel","sequence":"additional","affiliation":[{"name":"The Mel and Enid Zuckerman College of Public Health and the College of Medicine, University of Arizona , Tucson, Arizona , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenee","family":"Blanton","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention COVID-19 Response Team , Atlanta, Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janko","family":"Nikolich-Zugich","sequence":"additional","affiliation":[{"name":"The Mel and Enid Zuckerman College of Public Health and the College of Medicine, University of Arizona , Tucson, Arizona , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S","family":"Thiese","sequence":"additional","affiliation":[{"name":"Department of Family and Preventive Medicine, University of Utah Health , Salt Lake City, Utah , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Flores","family":"Pleasants","sequence":"additional","affiliation":[{"name":"Abt Associates, Inc , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley L","family":"Fowlkes","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention COVID-19 Response Team , Atlanta, Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Lutrick","sequence":"additional","affiliation":[{"name":"The Mel and Enid Zuckerman College of Public Health and the College of Medicine, University of Arizona , Tucson, Arizona , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayan","family":"Dunnigan","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Health , Temple, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young M","family":"Yoo","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention COVID-19 Response Team , Atlanta, Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Rose","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Health , Temple, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Groom","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northwest Center for Health Research , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Meece","sequence":"additional","affiliation":[{"name":"Marshfield Clinic Research Institute , Marshfield, Wisconsin , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith G","family":"Wesley","sequence":"additional","affiliation":[{"name":"Abt Associates, Inc , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Schaefer-Solle","sequence":"additional","affiliation":[{"name":"the Leonard M. Miller School of Medicine, University of Miami , Miami, Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Louzado-Feliciano","sequence":"additional","affiliation":[{"name":"the Leonard M. Miller School of Medicine, University of Miami , Miami, Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J","family":"Edwards","sequence":"additional","affiliation":[{"name":"Abt Associates, Inc , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E W","family":"Olsho","sequence":"additional","affiliation":[{"name":"Abt Associates, Inc , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G","family":"Thompson","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention COVID-19 Response Team , Atlanta, Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"2022082503024086900_CIT0001","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2034545","article-title":"Antibody status and incidence of SARS-CoV-2 infection in health care workers","volume":"384","author":"Lumley","year":"2021","journal-title":"N Engl J Med"},{"key":"2022082503024086900_CIT0002","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"2022082503024086900_CIT0003","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1080\/22221751.2020.1823890","article-title":"SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease","volume":"9","author":"Wang","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2022082503024086900_CIT0004","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41423-020-00588-2","article-title":"A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity","volume":"18","author":"Legros","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2022082503024086900_CIT0005","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1080\/21645515.2016.1183077","article-title":"Effect of antipyretic analgesics on immune responses to vaccination","volume":"12","author":"Saleh","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2022082503024086900_CIT0006","doi-asserted-by":"crossref","first-page":"e28925","DOI":"10.2196\/28925","article-title":"COVID-19 infection, reinfection, and vaccine effectiveness in a prospective cohort of Arizona frontline\/essential workers: the AZ HEROES Research Protocol","volume":"10","author":"Lutrick","year":"2021","journal-title":"JMIR Res Protoc"},{"key":"2022082503024086900_CIT0007","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2107058","article-title":"Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines","volume":"385","author":"Thompson","year":"2021","journal-title":"N Engl J Med"},{"key":"2022082503024086900_CIT0008","first-page":"e31574","article-title":"Research on the Epidemiology of SARS-CoV-2 in Essential Response personnel (RECOVER) study: protocol for a multi-site longitudinal cohort","volume":"10","author":"Edwards","year":"2021","journal-title":"J Med Internet Res"},{"key":"2022082503024086900_CIT0009","doi-asserted-by":"crossref","first-page":"109518","DOI":"10.1016\/j.celrep.2021.109518","article-title":"Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms","volume":"36","author":"Peluso","year":"2021","journal-title":"Cell Rep"},{"key":"2022082503024086900_CIT0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"2022082503024086900_CIT0011","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"2022082503024086900_CIT0012","doi-asserted-by":"crossref","first-page":"101018","DOI":"10.1016\/j.eclinm.2021.101018","article-title":"Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals","volume":"38","author":"Demonbreun","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2022082503024086900_CIT0013","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-021-03696-9","article-title":"Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"2022082503024086900_CIT0014","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.06.455491","article-title":"High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibo","author":"Schmidt","year":"2021","journal-title":"bioRxiv"},{"key":"2022082503024086900_CIT0015","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMc2101667","article-title":"Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine","volume":"384","author":"Krammer","year":"2021","journal-title":"N Engl J Med"},{"key":"2022082503024086900_CIT0016","doi-asserted-by":"crossref","first-page":"eabi6950","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci Immunol"},{"key":"2022082503024086900_CIT0017","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(21)00501-8","article-title":"Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals","volume":"397","author":"Manisty","year":"2021","journal-title":"Lancet"},{"key":"2022082503024086900_CIT0018","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1001\/jama.2021.3341","article-title":"Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2","volume":"325","author":"Saadat","year":"2021","journal-title":"JAMA"},{"key":"2022082503024086900_CIT0019","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1001\/jama.2021.15125","article-title":"Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273","volume":"326","author":"Steensels","year":"2021","journal-title":"JAMA"},{"key":"2022082503024086900_CIT0020","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.15585\/mmwr.mm7038e1","article-title":"Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions\u2014United States, March-August 2021","volume":"70","author":"Self","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022082503024086900_CIT0021","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.18.21260732","article-title":"Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines","author":"Naranbhai","year":"2021","journal-title":"medRxiv"},{"key":"2022082503024086900_CIT0022","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/s41591-021-01583-4","article-title":"BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar","volume":"7","author":"Tang","year":"2021","journal-title":"Nat Med"},{"key":"2022082503024086900_CIT0023","doi-asserted-by":"publisher","DOI":"10.1101\/2021.10.10.21264827","article-title":"Heterologous SARS-CoV-2 booster vaccinations\u2014preliminary report","author":"Atmar","year":"2021","journal-title":"medRxiv"},{"key":"2022082503024086900_CIT0024","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2107058","article-title":"Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines","volume":"385","author":"Thompson","year":"2021","journal-title":"N Engl J Med"},{"key":"2022082503024086900_CIT0025","first-page":"979","article-title":"FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system","volume":"2","author":"Pawlowski","year":"2021","journal-title":"Med (NY)"},{"key":"2022082503024086900_CIT0026","doi-asserted-by":"crossref","first-page":"495","DOI":"10.15585\/mmwr.mm7013e3","article-title":"Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers\u2014eight U.S. locations, December 2020-March 2021","volume":"70","author":"Thompson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022082503024086900_CIT0027","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJMoa2110362","article-title":"Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings","volume":"385","author":"Thompson","year":"2021","journal-title":"N Engl J Med"},{"key":"2022082503024086900_CIT0028","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.09.21261290","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy trial","author":"Gilbert","year":"2021","journal-title":"medRxiv"},{"key":"2022082503024086900_CIT0029","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.21.21258528","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","author":"Feng","year":"2021","journal-title":"medRxiv"},{"key":"2022082503024086900_CIT0030","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"2022082503024086900_CIT0031","doi-asserted-by":"crossref","first-page":"584251","DOI":"10.3389\/fmicb.2020.584251","article-title":"Anti-spike, anti-nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic individuals","volume":"11","author":"Brochot","year":"2020","journal-title":"Front Microbiol"},{"key":"2022082503024086900_CIT0032","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/infdis\/jiaa618","article-title":"Dynamics of neutralizing antibody titers in the months after severe acute respiratory syndrome coronavirus 2 infection","volume":"223","author":"Crawford","year":"2021","journal-title":"J Infect Dis"},{"key":"2022082503024086900_CIT0033","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1093\/cid\/ciab004","article-title":"The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers","volume":"73","author":"Lumley","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022082503024086900_CIT0034","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/s41467-021-21444-5","article-title":"Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19","volume":"12","author":"Wheatley","year":"2021","journal-title":"Nat Commun"},{"key":"2022082503024086900_CIT0035","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/s41591-020-0995-0","article-title":"Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19","volume":"26","author":"Juno","year":"2020","journal-title":"Nat Med"},{"key":"2022082503024086900_CIT0036","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"Seow","year":"2020","journal-title":"Nat Microbiol"},{"key":"2022082503024086900_CIT0037","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"},{"key":"2022082503024086900_CIT0038","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/cid\/ciz1034","article-title":"Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial","volume":"71","author":"Cowling","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022082503024086900_CIT0039","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.chom.2020.06.021","article-title":"Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2","volume":"28","author":"Case","year":"2020","journal-title":"Cell Host Microbe"},{"key":"2022082503024086900_CIT0040","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab1038\/42332537\/ciab1038.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/1\/e827\/45513920\/ciab1038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/1\/e827\/45513920\/ciab1038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T23:05:17Z","timestamp":1661382317000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/1\/e827\/6470720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,20]]},"published-print":{"date-parts":[[2022,8,24]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab1038","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.10.20.21265171","asserted-by":"object"}]},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2021,12,20]]}}}